<code id='E801CF8A30'></code><style id='E801CF8A30'></style>

<acronym id='E801CF8A30'></acronym>

<center id='E801CF8A30'><center id='E801CF8A30'><tfoot id='E801CF8A30'></tfoot></center><abbr id='E801CF8A30'><dir id='E801CF8A30'><tfoot id='E801CF8A30'></tfoot><noframes id='E801CF8A30'>

<optgroup id='E801CF8A30'><strike id='E801CF8A30'><sup id='E801CF8A30'></sup></strike><code id='E801CF8A30'></code></optgroup>

<b id='E801CF8A30'><label id='E801CF8A30'><select id='E801CF8A30'><dt id='E801CF8A30'><span id='E801CF8A30'></span></dt></select></label></b><u id='E801CF8A30'></u>

~~<i id='E801CF8A30'><strike id='E801CF8A30'><tt id='E801CF8A30'><pre id='E801CF8A30'></pre></tt></strike></i>~~

Home» explore» explore

explore

explore

author：Wikipedia 2025-09-27 17:36:09 Page View：737

Alexis Borisy — Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

advertisement

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Addressing health care workers' trauma can help fight burnout
Next article： Wildfire smoke exposes gaps in outdoor worker protections

explore

The cancer drug shortage isn’t new — and neither are the solutions

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Physician executives need more than on

Physician executives need more than on

AdobeItshouldbeobviousthatmedicalschoolandclinicalexperience,inthemselves,can’tfullypreparesomeonefo

Supreme Court strikes down use of affirmative action

Supreme Court strikes down use of affirmative action

ActivistsdemonstratedastheSupremeCourtheardoralargumentsonapairofaffirmativeactioncasesinOctober2022

FDA poised to publish guidelines for clinical trial diversity

AdobeTheFoodandDrugAdministrationispoisedtotelldrugandmedicaldevicemakershowtobetterincludepeopleofc

read more